DEF: Cardinal Health Reports Strong FY25, Boosts Specialty & At-Home Solutions

Cardinal Health achieved double-digit profit growth across all operating segments in fiscal 2025, driven by strategic acquisitions and operational efficiencies, despite a major contract expiration.

Summary

• Fiscal 2025 was a strong and transformative year, marked by accelerated momentum and disciplined execution against strategic plans.
• Achieved double-digit profit growth across all five operating segments, with enterprise operating earnings and EPS increasing significantly.
• Delivered $2.4 billion in operating cash flow and returned over $1.2 billion to shareholders through dividends and share repurchases.
• Overcame operational challenges stemming from a large customer contract expiration (OptumRx) at the end of fiscal 2024.
• Completed strategic acquisitions totaling $5.3 billion in the Pharmaceutical and Specialty Solutions segment (Integrated Oncology Network, GI Alliance, Urology America) and the at-Home Solutions business (Advanced Diabetes Supply Group).
• Launched The Specialty Alliance multi-specialty management services organization (MSO) platform, now supporting approximately 2,200 providers across 28 states and over 450 sites of care.
• The Board's composition was strengthened with the addition of new independent directors, Robert Musslewhite and Sudhakar Ramakrishna, and new committee chairs were appointed.
• Engaged with shareholders representing 32% of outstanding shares during the summer of 2025 to discuss strategy, governance, and compensation.
• The Annual Meeting of Shareholders is scheduled virtually for November 5, 2025, to vote on director elections, executive compensation, and auditor ratification.

Sentiment

Score: 8

Explanation: The company demonstrated robust financial performance in fiscal 2025, achieving double-digit profit growth across all segments and significantly outperforming the S&P 500 Health Care Index in TSR over three years. Strategic acquisitions in high-growth areas like Specialty and at-Home Solutions, coupled with disciplined execution and operational efficiencies, position the company for continued long-term value creation. While revenue was impacted by a contract expiration, the underlying profitability and strategic investments indicate strong forward momentum. The enhanced board composition and commitment to strong corporate governance further support a positive outlook.

Positives

• Achieved strong fiscal 2025 financial performance with double-digit profit growth across all five operating segments.
• GAAP operating earnings increased by 83% year-over-year to $2.3 billion, reflecting a favorable comparison to the prior year.
• Non-GAAP operating earnings increased by 15% year-over-year to $2.8 billion, driven by segment profit increases in Pharma and Other.
• GAAP diluted EPS increased by 87% year-over-year to $6.45, benefiting from the absence of prior year's goodwill impairment charges.
• Non-GAAP diluted EPS increased by 9% year-over-year to $8.24, reflecting increased non-GAAP operating earnings and a lower share count.
• Pharma segment profit grew 12% year-over-year, GMPD segment profit increased 47%, and Other segment profit increased 22%.
• Generated $2.4 billion in operating cash flow.
• Returned over $1.2 billion to shareholders, including $750 million in share repurchases and $494 million in dividends.
• Strategic acquisitions in Specialty (ION, GI Alliance, Urology America) and at-Home Solutions (Advanced Diabetes Supply Group) align with long-term growth strategy in important and growing markets.
• Launched The Specialty Alliance multi-specialty MSO platform, enhancing capabilities in gastroenterology and urology.
• Board composition strengthened with the addition of Robert Musslewhite (healthcare technology, data analytics) and Sudhakar Ramakrishna (cybersecurity, enterprise software, IT infrastructure).
• Michelle Brennan appointed Chair of the Governance and Sustainability Committee and Dave Evans appointed Chair of the Audit Committee, leveraging their substantial board leadership experience.
• Shareholders demonstrated strong support for the executive compensation program in 2024, with 90% of votes cast in favor of say-on-pay.
• Fiscal 2023-2025 Performance Share Units (PSUs) settled at 212% of target, reflecting over-performance against financial goals and a 20% upward modifier for achieving the 100th percentile of the S&P 500 Health Care Index TSR.
• The three-year Total Shareholder Return (TSR) was 235.5%, significantly outperforming the S&P 500 Health Care Index's 9.4% over the same period.

Negatives

• Revenue was $222.6 billion, down 2% year-over-year, primarily reflecting the expiration of pharmaceutical distribution contracts with OptumRx at the end of fiscal 2024.
• Operating cash flow decreased by 37% year-over-year to $2.4 billion, reflecting the impact of unwinding the negative net working capital associated with the expired OptumRx contracts.
• The Compensation Committee exercised negative discretion to reduce the final annual incentive payouts for corporate function (to 136%), GMPD segment (to 80%), and Pharma segment (to 130%) employees to contribute to funding bonus payments for other eligible employees.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from historical experience or future results.
• Potential risks and uncertainties include factors found in news releases and SEC filings, including the Annual Report on Form 10-K for fiscal 2025.
• The company operates in an uncertain and dynamic macroeconomic environment.
• Operational challenges may arise from large customer contract expirations.
• Cybersecurity and other major information technology risk exposures, including artificial intelligence, require ongoing oversight and investment.
• Risks associated with operations, including quality, legal, and regulatory compliance (e.g., healthcare fraud and abuse, antitrust, data privacy and security, anti-bribery, anti-corruption, product quality and safety).
• Controlled substance distribution risks, including compliance with federal and state regulations and the injunctive relief terms of the national opioid settlement, and ongoing opioid litigation and investigations.
• Third-party risks and human factors in information technology pose potential challenges.
• Environmental, social, and political issues and risks could potentially impact the company.

Future Outlook

The Board is enthusiastic about overseeing the execution of strategic priorities designed to achieve growth plans for fiscal 2026 and beyond. The company plans to continue its strategic focus on maximizing shareholder value through organic and inorganic investments, further building its presence in important and growing markets like Specialty and at-Home Solutions. This includes enhancing capabilities to become a multi-specialty leader and growing the impact of management services organization platforms across autoimmune, urology, and oncology. The company also aims to accelerate momentum across its high-potential growth businesses and continue the multi-year transformation of the Global Medical Products and Distribution segment.

Management Comments

• "Fiscal 2025 was a strong and transformative year for Cardinal Health. We accelerated our momentum, executing against our clear strategy and delivering on our plans with disciplined execution." Gregory B. Kenny, Chairman of the Board.
• "Our focus on driving simplification and operational efficiencies in our core while investing strategically for growth is enabling our continued evolution as we meet the needs of our customers and patients." Gregory B. Kenny, Chairman of the Board.
• "Our success would not be possible without the commitment of our employees, who remain focused on our mission to improve the lives of people every day." Gregory B. Kenny, Chairman of the Board.
• "Following a strong fiscal 2025, the Board is excited to oversee execution of the company’s strategic priorities, which are designed to achieve our plans for growth for fiscal 2026 and beyond." Gregory B. Kenny, Chairman of the Board.

Industry Context

Cardinal Health operates as a global healthcare services and products company, providing customized solutions across the healthcare continuum. The strategic acquisitions in Specialty (gastroenterology, urology, oncology) and at-Home Solutions align with broader industry trends towards specialized care, patient-centric models, and the growing demand for home-based healthcare services. These moves position the company to capitalize on higher-margin opportunities and key secular trends within the evolving healthcare landscape. The company's emphasis on supply chain efficiency and integrated care coordination reflects the industry's ongoing need for streamlined operations and improved patient outcomes. Its use of the S&P 500 Health Care Index for Total Shareholder Return (TSR) comparison underscores its competitive positioning within the broader healthcare sector.

Comparison to Industry Standards

• The company's three-year Total Shareholder Return (TSR) of 235.5% significantly outperformed the S&P 500 Health Care Index's TSR of 9.4% over the same period (through June 30, 2025), indicating superior shareholder value creation relative to its broader healthcare industry peers.
• The Fiscal 2023-2025 Performance Share Units (PSUs) payout was increased by 20% due to the company's relative TSR finishing in the 100th percentile of the S&P 500 Health Care Index, demonstrating top-tier performance against this benchmark.
• The Comparator Group used for executive compensation, which includes companies like Abbott Laboratories, McKesson Corporation, CVS Health Corporation, FedEx Corporation, and UnitedHealth Group Incorporated, reflects a mix of direct competitors and companies with similar business models or talent markets.
• The company's revenue is in the top quintile of its Comparator Group, while its market capitalization is in the bottom quintile, suggesting a large operational footprint relative to its market valuation compared to its peers.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation (recoveries)/charges, net, which include loss contingencies for certain litigation and regulatory matters and income from the favorable resolution of litigation, are excluded from non-GAAP measures due to their unpredictable nature and non-ordinary course of business.
• The Risk Oversight Committee receives quarterly updates on the company's controlled substance monitoring program, ongoing compliance with federal and state regulations, legislative and regulatory developments, compliance with the injunctive relief terms of the national opioid settlement, and the status of opioid litigation and investigations.

Related Party Transactions

• Michelle M. Brennan, a director, served as interim CEO of Masimo, a global medical technology company, from September 24, 2024, to February 12, 2025.
• Cardinal Health had a pre-existing, arm's-length commercial contract with Masimo for product purchases and made approximately $76 million in payments to Masimo during the period Ms. Brennan served as interim CEO.
• These transactions were approved by the Audit Committee in accordance with the company's Related Person Transactions Policy, and Ms. Brennan was not involved in related discussions or decisions.

Stakeholder Impact

• Shareholders benefited from strong financial performance, significant shareholder returns ($1.2 billion in dividends and share repurchases), and exceptional three-year Total Shareholder Return (235.5%).
• Employees are impacted by 'Our Path Forward' goals focused on well-being and culture, and eligible employees received bonus payments recognizing their contributions to fiscal 2025 performance.
• Customers are expected to benefit from strategic investments aimed at modernizing distribution, enhancing service capabilities, and expanding capacity, as well as from acquisitions in Specialty and at-Home Solutions designed to meet their evolving needs.
• Suppliers are part of the company's focus on enhancing supply chain efficiency.
• Patients are the ultimate beneficiaries of the company's mission to improve lives daily by providing essential products and solutions.

Next Steps

• Shareholders will vote on the election of 12 director nominees, an advisory vote to approve named executive officer compensation, and the ratification of Ernst & Young LLP as independent auditor at the Annual Meeting on November 5, 2025.
• The Board will oversee the execution of strategic priorities designed to achieve growth plans for fiscal 2026 and beyond.
• Continued investment to modernize and expand the distribution footprint, enhance customer service capabilities, and add capacity across networks.
• Further build presence in the Specialty and at-Home Solutions markets.
• Grow the impact of management services organization platforms across autoimmune, urology, and oncology.
• Ongoing Board refreshment and succession planning will continue.
• Annual cash retainer, RSU grant value, and committee chair additional annual retainers for non-management directors will increase effective November 15, 2025.
• The company will continue its shareholder engagement efforts.

Key Dates

Recommendation

The company delivered exceptional financial results in fiscal 2025, marked by double-digit profit growth across all operating segments and a remarkable 235.5% three-year Total Shareholder Return, significantly outperforming the S&P 500 Health Care Index. Despite a revenue decline due to a contract expiration, the underlying profitability and strategic investments in high-growth areas like Specialty and at-Home Solutions demonstrate strong operational resilience and a clear path for future expansion. The proactive board refreshment and robust corporate governance practices further enhance confidence in long-term value creation. The strong performance and strategic positioning warrant a 'strong buy' recommendation.

Keywords

Healthcare, Pharmaceutical distribution, Medical products, Specialty solutions, At-Home Solutions, Acquisitions, Corporate governance, Executive compensation, SEC filing, Proxy statement, Financial performance, Operating earnings, EPS, Cash flow, Shareholder return, Board refreshment, Risk management, Cybersecurity, Artificial intelligence, Regulatory compliance, OptumRx